omeprazole has been researched along with Celiac Disease in 8 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Celiac Disease: A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 9.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 5.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| " This review emphasizes the importance of personalized medicine for individuals with gastroesophageal disorders that require long-term use of PPIs." | 3.01 | A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition. ( Brooks, AE; McMillan, A; Perez, C, 2023) |
| "Celiac disease is an autoimmune enteropathy characterized by an aberrant immune response to ingested gluten in genetically predisposed individuals." | 2.94 | Celiac disease serology and gut microbiome following proton pump inhibitor treatment. ( Abrams, JA; Alaedini, A; Freedberg, DE; Green, PHR; Jang, S; Lebwohl, B, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| McMillan, A | 1 |
| Perez, C | 1 |
| Brooks, AE | 1 |
| Jang, S | 1 |
| Lebwohl, B | 1 |
| Abrams, JA | 1 |
| Green, PHR | 1 |
| Freedberg, DE | 1 |
| Alaedini, A | 1 |
| Veres, G | 1 |
| Korponay-Szabó, I | 1 |
| Maka, E | 1 |
| Glasz, T | 1 |
| Mamula, P | 1 |
| Schuster, V | 2 |
| Tefs, K | 2 |
| Papp, M | 1 |
| Dezsöfi, A | 1 |
| Arató, A | 1 |
| Kloesel, B | 1 |
| Chandan, VS | 1 |
| Alexander, GL | 1 |
| Hershko, C | 1 |
| Hoffbrand, AV | 1 |
| Keret, D | 1 |
| Souroujon, M | 1 |
| Maschler, I | 1 |
| Monselise, Y | 1 |
| Lahad, A | 1 |
| Bruno, MJ | 1 |
| Rauws, EA | 1 |
| Hoek, FJ | 1 |
| Tytgat, GN | 1 |
| Tran, TM | 1 |
| Van den Neucker, A | 1 |
| Hendriks, JJ | 1 |
| Forget, P | 1 |
| Forget, PP | 1 |
| Heijerman, HG | 1 |
| Lamers, CB | 1 |
| Bakker, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Celiac Disease
| Article | Year |
|---|---|
A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition.
Topics: Celiac Disease; Genetic Predisposition to Disease; Humans; Omeprazole; Proton Pump Inhibitors | 2023 |
3 trials available for omeprazole and Celiac Disease
| Article | Year |
|---|---|
Celiac disease serology and gut microbiome following proton pump inhibitor treatment.
Topics: Actinomycetales; Adult; Alleles; Celiac Disease; Feces; Female; Gastrointestinal Microbiome; Gastroi | 2020 |
Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy.
Topics: Adult; Aged; Celiac Disease; Cimetidine; Double-Blind Method; Exocrine Pancreatic Insufficiency; Fem | 1994 |
Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis.
Topics: Adult; Capsules; Celiac Disease; Cystic Fibrosis; Double-Blind Method; Drug Interactions; Drug Thera | 1991 |
4 other studies available for omeprazole and Celiac Disease
| Article | Year |
|---|---|
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Topics: Abdominal Pain; Biopsy, Needle; Blood Chemical Analysis; Celiac Disease; Child; Deficiency Diseases; | 2011 |
An unusual referral for epigastric pain, nausea, abdominal bloating, diarrhea, and weight loss.
Topics: Abdominal Pain; Adult; Anti-Ulcer Agents; Biopsy; Celiac Disease; Diarrhea; Diet, Gluten-Free; Duode | 2012 |
Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Antibodies, Bacterial; Autoantibodies | 2005 |
Effects of a proton-pump inhibitor in cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Ch | 1998 |